Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Eisai GmbH, Lyoner Straße 36, 60528, Frankfurt am Main, Germany, E-mail: medinfo_de@eisai.net
Panretin 0.1% gel.
| Pharmaceutical Form |
|---|
|
Gel. Clear yellow gel. |
1 g of gel contains 1 mg alitretinoin (0.1%).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Alitretinoin |
Alitretinoin is a naturally-occurring endogenous hormone related to vitamin A, binds to and activates all known intracellular retinoid receptor subtypes (RAR, RAR, RAR, RXR, RXR, RXR). The efficacy of alitretinoin in treating KS lesions may be related to the demonstrated ability of alitretinoin to inhibit the in vitro growth of KS cells. |
| List of Excipients |
|---|
|
Ethanol |
Panretin gel is supplied in a multi-use 60 g epoxy-lined aluminium tube.
Each carton contains one tube of gel.
Eisai GmbH, Lyoner Straße 36, 60528, Frankfurt am Main, Germany, E-mail: medinfo_de@eisai.net
EU/1/00/149/001
Date of first authorization: 11 October 2000
Date of latest renewal: 27 September 2010
| Drug | Countries | |
|---|---|---|
| PANRETIN | Estonia, Lithuania, Poland, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
